Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

People with type 1 diabetes who rely on insulin injections to control their blood sugar levels are at risk for life-threatening hypoglycemic events in which their blood glucose levels drop dangerously low.

25 Jun 2013

Moderate-intensity exercise reduces fat deposits in people with diabetes mellitus

Moderate-intensity exercise reduces fat stored around the heart, in the liver and in the abdomen of people with type 2 diabetes mellitus, even in the absence of any changes in diet, according to a new study published online in the journal Radiology.

25 Jun 2013

Study finds that triple therapy corrects two core defects in type 2 diabetes

Patients with type 2 diabetes fare significantly better if they are started on three medications at the time of diagnosis than if they are prescribed a single drug and have other therapies added later, a San Antonio researcher said June 22 at the 73rd Scientific Sessions of the American Diabetes Association in Chicago.

25 Jun 2013

Study examines long-term effects on babies born to mothers with obstetric cholestasis

Babies born to mothers who suffer from a rare metabolic complication during pregnancy are programmed to be overweight, according to a study published today in the Journal of Clinical Investigation.

25 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Study: Multiple islet autoantibodies in children indicate risk of developing type 1 diabetes

A decade-long JDRF-funded study led by the Institute of Diabetes Research in Helmholtz Zentrum M-nchen, Germany, is providing a deeper understanding of the link between autoantibodies and the risk of developing type 1 diabetes, highlighting the importance of pre-diabetes research into possible preventions for the disease.

20 Jun 2013

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia—low blood sugar—compared with the commercially available insulin glargine, a new meta-analysis study finds.

19 Jun 2013

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

New research suggests that fetal exposure to the common environmental chemical bisphenol A, or BPA, causes increased inflammation in fat tissues after birth, which can lead to obesity and metabolic syndrome. Results of the animal study were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

19 Jun 2013

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

In the impassioned debates over healthcare, one fact is often lost - Americans pay more but get less for their health care than residents of other high-income countries. I believe we can change that. We can improve the quality of care and reduce our expenses, saving a trillion dollars or more a year, by making our health care system more efficient (William A. Haseltine, 6/17).

19 Jun 2013

Fetal exposure to BPA lowers testicular hormone in newborn boys

A new study links fetal exposure to a common chemical pollutant, bisphenol A (BPA), to defects of a testicular hormone in newborn boys with undescended testicles. The results, which were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco, suggest yet another potential harmful effect of BPA, which is widely used in many plastics, liners of food cans and dental sealants.

18 Jun 2013

Special type of IVF may increase risk for insulin resistance among children

A special type of in vitro fertilization, or IVF, may increase the risk for insulin resistance among children conceived in this way, according to a new study from Greece. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Women with polycystic ovary syndrome lose more weight when they take two drugs

Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

18 Jun 2013

Overweight women who skip breakfast experience acute insulin resistance

Overweight women who skip breakfast experience acute, or rapid-onset, insulin resistance, a condition that, when chronic, is a risk factor for diabetes, a new study finds. The results, which were presented Sunday at The Endocrine Society's 95th Annual Meeting in San Francisco, suggest that regularly skipping breakfast over time may lead to chronic insulin resistance and thus could increase an individual's risk for type 2 diabetes.

18 Jun 2013

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

UT Southwestern Medical Center researchers are seeking 150 adults with type 2 diabetes to take part in the local arm of a major national clinical trial that will compare benefits and side effects of four widely used therapies to lower blood-sugar levels.

18 Jun 2013

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

A team from the New York Stem Cell Foundation Research Institute and the Naomi Berrie Diabetes Center of Columbia University has generated patient-specific beta cells, or insulin-producing cells, that accurately reflect the features of maturity-onset diabetes of the young.

18 Jun 2013

Insulin News and Research

Further Reading

Promising approach to reduce risk of hypoglycemia in diabetes shows positive results

Moderate-intensity exercise reduces fat deposits in people with diabetes mellitus

Study finds that triple therapy corrects two core defects in type 2 diabetes

Study examines long-term effects on babies born to mothers with obstetric cholestasis

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Study: Multiple islet autoantibodies in children indicate risk of developing type 1 diabetes

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Research: Fetal exposure to BPA causes inflammation in fat tissues after birth

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

Fetal exposure to BPA lowers testicular hormone in newborn boys

Special type of IVF may increase risk for insulin resistance among children

Women with polycystic ovary syndrome lose more weight when they take two drugs

Overweight women who skip breakfast experience acute insulin resistance

Researchers to study benefits, side effects of four widely used therapies in adults with type 2 diabetes

Researchers use patient-specific stem cells to correct deficient insulin-producing cells

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News